论文部分内容阅读
最近世界卫生组织(WHO)发表了一个造血和淋巴组织肿瘤分类方案,该分类是由血液病理学会、欧洲血液病理学工作者协会和一百多名有造血系统肿瘤方面专长的国际上知名临床血液学家和科学家通力协作制定出来的。关于淋巴组织肿瘤,本分类方案只是对现已被广泛使用的修订欧美淋巴瘤(REAL)分类方案中的病种进行了加工。但迄今为止尚没有关于WHO髓系肿瘤分类的解说或理论依据方面的文章发表。本文的目的是简短概述WHO恶性髓系疾病的分类并提醒注意它与此前各种分类方案的主要不同点,并提供这些不同点的理论依据。
Recently, the World Health Organization (WHO) published a classification scheme for hematopoietic and lymphatic tumor by the Society of Hematopathology, the European Association of Hematopathologists and more than 100 internationally renowned clinical bloodstreams specializing in hematopoietic tumors Scientists and scientists worked together to develop it. With respect to lymphoid tissue tumors, this classification regimen only addresses the currently widely used revision of the European Classification of Lymphoma (REAL) classification schemes. However, no articles on the classification or rationale of WHO myeloid tumors have been published so far. The purpose of this article is to briefly outline the classification of the WHO malignant myelopathy and to note its main differences from previous classification schemes and to provide the rationale for these differences.